Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05325073 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruitingv4 Show 4 more changesShow less
    • Enrollment target: estimated 20 to confirmed 9
    • Primary completion date changed from estimate of Jun 30, 2023 to May 23, 2023
    • Study completion date: Jul 15, 2023 to Sep 30, 2024
    • Site details revised
  2. Primary completion date: Mar 31, 2023 to Jun 30, 2023
    • Study completion date: Jun 15, 2023 to Jul 15, 2023
    v3
  3. Primary completion date: Dec 31, 2022 to Mar 31, 2023v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The hypothesis of this proof-of-concept study is that EPO increases the frequency, stability and/or function of Tregs in liver transplant recipients. We also hypothesize that EPO will have a greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinical trial to utilize EPO in combination with everolimus as a more successful pathway toward tolerance.
Trial Details
NCT Number NCT05325073
Lead Sponsor Northwestern University
Conditions
(from sponsor)		 Liver Transplant Rejection
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov